News | April 07, 2010

New Jersey, New York-Region Get Access to Proton Therapy

April 7, 2010 - According to statistics from the American Cancer Society, an estimated 48,000 people in New Jersey and 101,000 in New York state were diagnosed with cancer in 2009, many of which will receive some form of radiation therapy.

Cancer survivors joined representatives from ProCure Treatment Centers Inc. (ProCure), Princeton Radiation Oncology (PRO), and CentraState Healthcare System to break ground on the ProCure Proton Therapy Center in Somerset.

The $160 million, 60,000-square-foot facility is the first proton therapy center to be built in the state. The facility will have four treatment rooms with the capacity to treat approximately 1,500 patients annually.

While most regions in the United States are limited to conventional radiation therapy treatments, patients in the New Jersey and New York area will have access to proton therapy. Research has shown that proton therapy causes fewer short- and long-term treatment side effects than traditional X-ray radiation therapy, diminishes the chances of secondary tumors and improves patients’ quality of life. The precision of proton therapy greatly reduces the type of damage often caused by radiation treatment because the majority of its energy is deposited directly in the tumor rather than in surrounding healthy tissue or nearby organs. Proton therapy is especially effective for treating a broad range of tumors including head and neck, brain, central nervous system, prostate, lung, sarcomas, gastrointestinal and many pediatric cancers.

For more information: www.procure.com

Related Content

DOSIsoft Receives FDA 510(k) Clearance for Planet Onco Dose Software
Technology | Information Technology | June 20, 2019
DOSIsoft announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market Planet...
New Data Demonstrates Safety Profile of GammaTile Therapy for Various Brain Tumors
News | Brachytherapy Systems | June 18, 2019
GT Medical Technologies Inc. announced the presentation of clinical data from a prospective study of GammaTile Therapy...
Black Men Less Likely to Adopt Active Surveillance for Low-Risk Prostate Cancer
News | Prostate Cancer | June 17, 2019
A new study reveals black men are less likely than white men to adopt an active surveillance strategy for their...
University Medical Center Groningen Performs First Automatic Log-based Proton Therapy Patient QA
News | Proton Therapy | June 14, 2019
IBA announced the physics team of University Medical Center Groningen (UMCG) in the Netherlands has developed and...
ASTRO Applauds New Prior Authorization Legislation
News | Radiation Therapy | June 07, 2019
The American Society for Radiation Oncology (ASTRO) released a statement applauding Congress’s introduction of...
IBA Dosimetry Launches myQA iON
News | Quality Assurance (QA) | June 07, 2019
IBA (Ion Beam Applications S.A.) announced the launch of myQA iON at the 2019 Particle Therapy Co-Operative Group (...
Study Identifies MRI-Guided Radiation Therapy as Growing Market Segment
News | Image Guided Radiation Therapy (IGRT) | June 06, 2019
Revenues from the magnetic resonance imaging (MRI)-guided radiation therapy systems market exceeded $220 million in...
RefleXion Opens New Manufacturing Facility for Biology-guided Radiotherapy Platform
News | Radiation Therapy | May 31, 2019
RefleXion Medical recently announced the opening of its new manufacturing facility at its headquarters in Hayward,...
Accuray Radixact

Accuray Radixact

Feature | Radiation Therapy | May 29, 2019 | By Jeff Zagoudis
While radiation therapy as a disciplin
Sponsored Content | Case Study | Radiation Therapy | May 29, 2019
The so-called “Grey Tsunami” of baby boomers using healthcare services isn’t taking the Radiation Medicine Program at